Fidelity Investments
LEGN icon

Fidelity Investments’s Legend Biotech LEGN Stock Holding History

Fidelity Investments’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840M Buy
29,093,899
+3,397,159
+13% +$91.6M 0.04% 375
2026
Q1 		$465M Buy
25,696,740
+1,428,517
+6% +$27.2M 0.02% 537
2025
Q4 		$528M Sell
24,268,223
-3,434,619
-12% -$98.4M 0.03% 487
2025
Q3 		$903M Buy
27,702,842
+2,032,531
+8% +$75M 0.05% 317
2025
Q2 		$911M Buy
25,670,311
+12,466,098
+94% +$404M 0.05% 305
2025
Q1 		$448M Sell
13,204,213
-242,799
-2% -$8.71M 0.03% 497
2024
Q4 		$438M Sell
13,447,012
-4,883,207
-27% -$202M 0.03% 526
2024
Q3 		$893M Buy
18,330,219
+708,620
+4% +$37.7M 0.05% 298
2024
Q2 		$780M Buy
17,621,599
+1,474,567
+9% +$68M 0.05% 309
2024
Q1 		$906M Buy
16,147,032
+3,349,038
+26% +$202M 0.06% 286
2023
Q4 		$770M Sell
12,797,994
-3,107,454
-20% -$197M 0.06% 291
2023
Q3 		$1.07B Sell
15,905,448
-1,140,050
-7% -$79.2M 0.09% 195
2023
Q2 		$1.18B Buy
17,045,498
+650,821
+4% +$42.5M 0.1% 181
2023
Q1 		$791M Buy
16,394,677
+1,253,099
+8% +$61.3M 0.07% 276
2022
Q4 		$756M Buy
15,141,578
+2,563,545
+20% +$124M 0.08% 258
2022
Q3 		$513M Buy
12,578,033
+5,914,329
+89% +$278M 0.05% 351
2022
Q2 		$367M Buy
6,663,704
+4,239,041
+175% +$179M 0.04% 480
2022
Q1 		$88.1M Buy
2,424,663
+1,613,155
+199% +$63.7M 0.01% 1124
2021
Q4 		$37.8M Buy
811,508
+169,308
+26% +$8.59M ﹤0.01% 1539
2021
Q3 		$32.5M Buy
642,200
+605,206
+1,636% +$25.2M ﹤0.01% 1612
2021
Q2 		$1.52M Hold
36,994
– – ﹤0.01% 2596
2021
Q1 		$1.07M Buy
36,994
+31,199
+538% +$851K ﹤0.01% 2570
2020
Q4 		$163K Sell
5,795
-277,101
-98% -$7.98M ﹤0.01% 2815
2020
Q3 		$8.73M Sell
282,896
-45,207
-14% -$1.52M ﹤0.01% 1876
2020
Q2 		$14M Buy
+328,103
New +$12.8M ﹤0.01% 1692

Other funds holding LEGN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments's LEGN Position: Q2 2026 in Review

Fidelity Investments increased its Legend Biotech (LEGN) stake by 13% in Q2 2026, buying an estimated $91.6M and bringing the position to 29,093,899 shares worth $840M. The position accounts for 0.04% of the portfolio, ranked #375.

Fidelity Investments first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.18B in Q2 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Fidelity Investments held 29,093,899 shares of Legend Biotech worth $840M as of Q2 2026.
  • Fidelity Investments bought 3,397,159 Legend Biotech shares in Q2 2026, an estimated $91.6M.
  • Legend Biotech made up 0.04% of Fidelity Investments's portfolio in Q2 2026, its #375 holding.
  • Fidelity Investments first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Legend Biotech position peaked at $1.18B in Q2 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.